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Highlights
 Obesity induces TSP1 expression in several tissues,
such as adipose tissue and liver.
 Macrophages are an important cellular source of
increased TSP1 in mouse NASH livers.
 Deletion of TSP1 in macrophages protects mice
from diet-induced NASH.
 SMPDL3B negatively regulates TSP1-mediated
macrophage activation.
Lay summary
Obesity-associated non-alcoholic fatty liver disease is
a most common chronic liver disease in the Western
world and can progress to liver cirrhosis and cancer.
No treatment is currently available for this disease.
The present study reveals an important factor
(macrophage-derived TSP1) that drives macrophage
activation and non-alcoholic fatty liver disease
development and progression and that could serve as
a therapeutic target for non-alcoholic fatty liver dis-
ease/steatohepatitis.
https://doi.org/10.1016/j.jhepr.2020.100193
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Macrophage-derived thrombospondin 1 promotes
obesity-associated non-alcoholic fatty liver disease
Taesik Gwag,1,† Raja Gopal Reddy Mooli,1,† Dong Li,1,† Sangderk Lee,1 Eun Y. Lee,2 Shuxia Wang1,*
1Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY 40536, USA; 2Department of Pathology and Laboratory
Medicine, University of Kentucky, Lexington, KY 40536, USA
JHEP Reports 2021. https://doi.org/10.1016/j.jhepr.2020.100193
Background & Aims: Thrombospondin 1 (TSP1) is a multifunctional matricellular protein. We previously showed that TSP1
has an important role in obesity-associated metabolic complications, including inflammation, insulin resistance, cardiovas-
cular, and renal disease. However, its contribution to obesity-associated non-alcoholic fatty liver disease/non-alcoholic
steatohepatitis (NAFLD or NASH) remains largely unknown; thus, we aimed to determine its role.
Methods: High-fat diet or AMLN (amylin liver NASH) diet-induced obese and insulin-resistant NAFLD/NASH mouse models
were utilised, in addition to tissue-specific Tsp1-knockout mice, to determine the contribution of different cellular sources of
obesity-induced TSP1 to NAFLD/NASH development.
Results: Liver TSP1 levels were increased in experimental obese and insulin-resistant NAFLD/NASH mouse models as well as
in obese patients with NASH. Moreover, TSP1 deletion in adipocytes did not protect mice from diet-induced NAFLD/NASH.
However, myeloid/macrophage-specific TSP1 deletion protected mice against obesity-associated liver injury, accompanied by
reduced liver inflammation and fibrosis. Importantly, this protection was independent of the levels of obesity and hepatic
steatosis. Mechanistically, through an autocrine effect, macrophage-derived TSP1 suppressed Smpdl3b expression in liver,
which amplified liver proinflammatory signalling (Toll-like receptor 4 signal pathway) and promoted NAFLD progression.
Conclusions: Macrophage-derived TSP1 is a significant contributor to obesity-associated NAFLD/NASH development and
progression and could serve as a therapeutic target for this disease.
© 2020 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
With the epidemic burden of obesity and metabolic diseases,
non-alcoholic fatty liver disease (NAFLD) has become the most
common chronic liver disease in the Western world. NAFLD
ranges from NAFL to non-alcoholic steatohepatitis (NASH), and
can progress to cirrhosis and HCC. The rates for obesity-
associated NAFLD/NASH continue to rise steadily.1,2 Notably,
there is no NAFLD/NASH therapy currently available. Lifestyle
interventions, such as diet and exercise, are the only treatments
available to patients with NAFLD. However, these interventions
do not achieve satisfactory results. Therefore, an effective alter-
native strategy is urgently needed.
The pathogenesis of NAFLD/NASH is complex and controlled
by coordinated actions of liver cells (i.e. hepatocytes, Kupffer cells
[KCs]/macrophages, hepatic stellate cells, and endothelial cells).
Accumulative experimental and clinical data demonstrate that
macrophages have an important role in the initiation and pro-
gression of NAFLD.3–9 KCs and infiltrating monocyte-derived
macrophages (MDMs) are two hepatic macrophage populations
that undergo expansion and functional changes during NASH
development.4,8,10–12 However, the driving factors that induce
such changes in liver macrophages remain to be determined.
Thrombospondin 1 (TSP1), a 420–450-kDa homotrimer with
individual subunits of 145 kDa, is a multifunctional matricellular
protein comprising several domains that can interact with different
cell surface receptors. It also has a role in cardiovascular and renal
diseases.13,14 In addition, TSP1 is involved in tissue injury, inflam-
matory diseases, and NAFLD.15–17 Recent studies demonstrated a
novel role for TSP1 in both the recruitment and proinflammatory
activation of macrophages.18 Furthermore, TSP1-dependent mod-
ulation of macrophage function contributes to obesity-associated
complications, such as chronic inflammation and insulin resis-
tance.19,20 However, whether TSP1 could serve as an important
factor that drives macrophage activation and NAFLD development
andprogression isunknownand is investigated in the current study.
In this study, we show that TSP1 levels are increased in both
animal and human NASH livers. By utilisation of tissue-specific
TSP1-deficient mice in diet-induced obesity and insulin-
resistant NAFLD/NASH models, we demonstrate that TSP1 dele-
tion in adipocytes does not protect mice from obesity-associated
NAFLD/NASH. However, myeloid/macrophage-specific TSP1
deficiency protects mice from obesity-associated liver inflam-
mation and fibrosis. This study provides strong in vivo evidence
that macrophage-derived TSP1 is an important contributor to
obesity-associated NAFLD/NASH.
Keywords: TSP1; Obesity; NAFLD; NASH; SMPDL3B; Macrophage.
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Material and methods
Mice and diets
All the experiments involving mice conformed to the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals and were approved by the University of Kentucky
Institutional Animal Care and Use Committee.
Animals were housed individually in standard cages at 22C
in a 12:12-h light–dark cycle.
Mouse breeding
Female Tsp1 floxed mice (Tsp1fl/fl)20 were bred with male Cre
mice (Lyz-Cre for macrophage-specific deletion: Tsp1DMV). Fe-
male offspring with a Tsp1fl/+Cre− genotype in the first generation
were then bred with male Tsp1fl/+Cre+ mice. Pups with a
Tsp1fl/fl/Cre+ genotype, Tsp1fl/fl/Cre− mice and littermate controls
were used for the study.
AMLN diet-induced NAFLD/NASH
Male C57BL/6 mice (8-weeks old, Jackson Laboratories, Bar Har-
bor, ME, USA) were allowed ad libitum access to an amylin liver
NASH (AMLN) diet (40% fat; 22% fructose and 2% cholesterol;
D09100301, Research Diets, Inc, NJ, USA) and low-fat diet (LFD)
(10% kcal, D1250B, Research Diets, Inc, NJ) (a control diet). The
experiments were carried out with different time periods of 3
and 8 months to generate NAFL and NASH models, respectively.
Each group contained 8–10 animals.
High-fat diet-induced NAFLD/NASH
The experiment was performed on 8-week-old male Tsp1fl/fl,
Tsp1DMV mice and their age and sex-matched littermates as con-
trols. Mice were fed either a high-fat diet (HFD; 60% kcal, D12492)
or LFD (10% kcal, D1250B) for 32 weeks with standard laboratory
water. Each group contained 8 mice. Body weights were measured
weekly. At the end of the study, mice were euthanised. Blood was
collected and the livers were harvested for analysis.
Analysis of Tsp1 expression in available liver scRNA-Seq data sets of
3 controls and 3 mice with AMLN diet-induced NASH (GSE129516)
Seurat single-cell RNA sequencing (scRNA-seq) analysis R tools
(https://satijalab.org/seurat/v3.2/immune_alignment.html) were
utilised for clustering and cell type assignment of data sets from
GSE129516.11 A total of 22 clusters were identified and TSP1
expression in these clusters was further analysed.
Liver histology and NAFLD score
Liver histology and NAFLD activity score (NAS) were assessed using
H&E stains in paraffin-embedded sections by using the standard
method as previously described,21 a composite parameter based on
separate scores for steatosis (0–3), lobular inflammation (0–3), and
hepatocellular ballooning (0–2). Liver fibrosis was assessed using
Sirius Red and/or Mason’s Trichrome stains in paraffin-embedded
sections. The total positive staining (reported as the percentage of
the total area) was assessed from 3–4 representative sections from
each animal using Image J software. Details on the liver slides from
human patients have been provided in the “Supplementary
materials and methods”.
Liver and plasma parameters
Total hepatic lipid was extracted from frozen livers using pro-
tocols as previously described.22 Liver or plasma triacylglycerol
(TG) and total cholesterol levels were measured enzymatically
by using kits from the Wako Chemicals. Plasma alanine
aminotransferase (ALT) and aspartate aminotransferase (AST)
levels were measured by using the kits from Bioassay Systems
according to the manufacture instructions.
Liver RNA-Seq transcriptome sequencing
Total RNA from liver samples of LFD or HFD-fed Tsp1fl/fl and
Tsp1Dmɸ mice was extracted using the RNeasy Mini Kit (Qiagen,
USA) and submitted to the BGI Americas (San Jose, CA, USA) for
RNA-Seq transcriptome sequencing using the BGISEQ-500 plat-
form. Data analysis was also performed by BGI Americas. DEseq2
algorithms were used to detect differentially expressed genes
(DEGs) between 2 groups. Genes exhibiting false-adjusted p
value <0.05 and the log2-fold change >−1 or <−−1 were considered
significant. Data were deposited in the Gene Expression Omnibus
with accession number GSE155973.
Real-time quantitative PCR
Total RNA from frozen liver tissues or cells was extracted using
RNeasy Mini Kit (Qiagen). RNA was reverse transcribed to cDNA
using a High Capacity cDNA Reverse Transcription Kit (Invi-
trogen, Carlsbad, CA, USA). Real-time quantitative PCR was per-
formed on a MyiQ Real-time PCR Thermal Cycler (Bio-Rad) with
SYBR Green PCR Master Kit (Qiagen). Relative mRNA expression
was calculated using the MyiQ system software as previous
reported19 and normalised to b-actin mRNA levels. All primer
sequences utilised in this study are detailed in Table 1.
Western blotting
Total protein was extracted from frozen liver tissue or cultured
cells. From each sample, 30 lg protein was separated in a 10%
SDS-polyacrylamide gel electrophoresis and transferred onto a
nitrocellulose membrane. Protein expression was determined by
immunoblotting with the following antibodies: anti-TSP1 (Novus
Biologicals), anti-a-SMA (Sigma), anti-SMPDL3B (Proteintech, IL,
USA), anti-Toll-like receptor 4 (anti-TLR4) (Sigma), and anti-b-
actin (Sigma). Membranes were blocked and then incubated
with primary antibodies, followed by incubation with appro-
priate horseradish peroxidase-conjugated secondary antibodies.
Labelled proteins were detected with an enhanced chem-
iluminescence system (Pierce).
Cell culture and treatment
RAW264.7 cell experiments
RAW264.7 cells (macrophage cell line from ATCC) were cultured
and treated with the recombinant TSP1 (5 lg/ml, R&D system)
for different time periods, and then harvested. SMPDL3B levels
(mRNA and protein) in these cells were determined by quanti-
tative (q)PCR and Western blotting, respectively. In addition,
proinflammatory cytokine expression in these cells was deter-
mined by qPCR. In another set of experiments, RAW264.7 cells
were transiently transfected with a SMPDL3B expression vector
(pcDNA3.1-Smpdl3b from GenScript) or an empty control vector
by using the FuGene 6 transfection reagent (Promega). After 48
h, cells were treated with TSP1 (5 lg/ml) for 6–24 h and the
expression of SMPDL3B or proinflammatory cytokines was
determined by qPCR. Interleukin (IL)-1b or tumour necrosis
factor (TNF)-a levels in the cell condition media were deter-
mined by ELISA.
Primary mouse liver macrophage (KC) experiments
KCs were isolated from 6–8-week-old male C57BL6 mice using a
2-step Percoll gradient [25%/50% (vol/vol)] centrifugation
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method as described previously23,24 and cultured in DMEM
media containing 10% FBS and 1% penicillin-streptomycin. For
characterisation, cells were fixed, stained with F4/80-Alexa 488
antibody (Bio-Rad, Hercules, CA, USA), mounted with a
mounting medium containing DAPI, and visualised with a fluo-
rescent microscope (Eclipse 80i, Nikon). In addition, KCs were
cultured and transfected with a SMPDL3B expression vector and
the effect of SMPDL3B overexpression on TSP1-induced proin-
flammatory cytokine production was determined as described
earlier for the RAW264.7 cells.
Statistical analysis
Statistical analysis was performed using Prism version 8.0.2
(GraphPad Software, San Diego, CA, USA). Data are expressed as
mean values ±SE. The statistical significance between 2 groups
was determined using a 2-tailed Student’s t-test. One-way
ANOVA followed by Bonferroni’s multiple comparisons test or
2-way ANOVA followed by Tukey’s multiple comparisons test
was applied for multigroup comparisons. A p value <0.05 was
considered to be statistically significant.
Results
TSP1 is upregulated in animal and human NAFLD and NASH
livers
In adult liver, TSP1 is expressed at very low levels under physi-
ological conditions,25 but increased under disease condi-
tions.26,27 We determined how the TSP1 level was altered in
NAFLD/NASH using a AMLN diet-induced NASH mouse model
(obese and insulin resistant).28 Simple steatosis was induced by 3
months of an AMLN diet, whereas steatohepatitis and liver
fibrosis were induced after 8 months. Liver TSP1 levels were
increased in mice with simple steatosis and more pronounced in
mice with NASH and fibrosis (Fig. 1A–D). Importantly, TSP1
expression was upregulated in human NAFLD liver as demon-
strated by immunohistochemical staining of liver sections. Pos-
itive TSP1 staining was seen in livers with steatosis and was
dramatically increased in NASH livers (Fig. S1). These data indi-
cate that increased TSP1 expression occurs in both animal and
human NAFLD and NASH livers.
To determine the cellular sources of increased TSP1 in NASH
livers, we analysed a mouse liver scRNA-seq data set
(GSE12951611), including 3 control and 3 AMLN diet-induced
NASH liver samples, identifying 22 clusters (Fig. 1E–G). TSP1
was expressed in hepatic stellate cells (HSCs), cholangiocytes and
macrophages, and was upregulated in NASH conditions. We also
analysed a human liver scRNA-seq data set (GSE136103) that
included healthy (n = 4–5) and cirrhotic liver samples (n = 4–5).12
TSP1 was expressed in endothelial cells (ECs), epithelial cells,
mesenchyme, and a subset of mononuclear phagocytes (MPs)
(Fig. S2). Interestingly, cirrhosis increased TSP1 expression in the
above-mentioned cell types except for MPs. This was in contrast
to the mouse data and could be explained by the different stages
of NAFLD analysed (NASH in mouse vs. cirrhosis in human).
Nonetheless, both mouse and human data consistently showed
that TSP1 is significantly expressed in liver nonparenchymal cells
and has minimal expression in hepatocytes.
Macrophage-specific TSP1 deficiency protects mice from
obesity-associated NASH
Tsp1 is expressed in liver macrophages and upregulated in NASH
conditions (Fig. 1). Therefore, we further determined its contri-
bution to obesity-associated NAFLD/NASH by utilisation of
macrophage-specific Tsp1 knockout mice (Tsp1Dmɸ).20 These
mice were fed a HFD for 8 months. Despite similar obesity and
hepatic steatosis, macrophage-specific TSP1 deletion was suffi-
cient to reduce diet-induced hepatic injury, indicated by reduced
plasma ALT and AST levels (Fig. 2A–C). HFD-induced liver Tsp1
expression was significantly reduced in macrophage-specific
Tsp1-knockout mice (Fig. 2D). These mice also had reduced
markers for liver inflammation (Tnf-a and Il-1b) and fibrosis
(Collagen I, Collagen III and a-smooth muscle actin [a-SMA])
(Figs. 2F–H and 3E). Furthermore, the reduction in liver fibrosis
was confirmed with Sirius Red staining in HFD-fed Tsp1Dmɸ mice
(Fig. 2E). Transforming growth factor (TGF)-b levels were com-
parable among all groups (Fig. 2F). Together, these data
demonstrate that macrophage-derived TSP1 is a significant
contributor to obesity-associated hepatic inflammation and
fibrosis.
The contribution of other cellular sources of obesity-induced
TSP1 (e.g. adipocytes29,30) to NAFLD/NSH development was
determined by utilisation of adipocyte-specific TSP1-knockout
mice (Tsp1Dadipo).20 Tsp1Dadipo mice fed a HFD for 8 months
developed similar levels of obesity (Fig. S3). Liver weight, tri-
glyceride levels, inflammatory markers, and positive Sirius red
staining in liver sections were also similar between HFD-fed
Tsp1Dadipo mice and control (Tsp1fl/fl) mice (Fig. S3B–D). Other
obesity-associated complications, such as glucose intolerance
and insulin resistance, developed similarly in knockout mice
compared with control (Tsp1fl/fl) mice.20 Collectively, these data
suggest that adipocyte-derived TSP1 does not contribute signif-
icantly to obesity-associated NAFLD.
Additionally, the contribution of hepatocyte-derived TSP1 to
NASH development was determined by utilisation of hepatocyte-
specific TSP1-knockout mice (Tsp1Dhep) (Fig. S4A). Control
(Tsp1fl/fl) and Tsp1Dhep mice developed a similar level of obesity
over 20 weeks of receiving an AMLN diet (Fig. S4B). Compared
with control mice, AMLN-fed Tsp1Dhep mice developed similar
Table 1. Primer sequences used in the study.
Primer Forward Reverse
TSP1 50-CTA GGT GTC CTG TTC CTG TTG-30 50-AAG GAA GCC AGG AAG ATG AAG-30
F4/80 50-CTT TGG CTA TGG GCT TCC AGT C-30 50-GCA AGG AGG ACA GAG TTT ATC GTG-30
IL-1b 50-TGG AGA GTG TGG ATC CCA AGC AAT-30 50-TGT CCT GAC CAC TGT TGT TTC CCA-30
TNF-a 50-AGC CGA TGG GTT GTA CCT-30 50-TGA GTT GGT CCC CCT TCT-30
TGF-b1 50-ACA ATT CCT GGC GTT ACC-30 50-GGC TGA TCC CGT TGA TTT-30
Collagen type I, a1 50-TTCTCCTGGCAAAGACGGACTCAA-30 50-AGGAAGCTGAAGTCATAACCGCCA-30
Collagen type III, a1 50-TCCTAACCAAGGCTGCAAGATGGA-30 50-TCCTAACCAAGGCTGCAAGATGGA-30
b-actin 50-GGCTGTATTCCCCTCCATCG-30 50-CCAGTTGGTAACAATGCCATGT-30
SMPDL3B 50-GGGACTACCTCTGCGATTCTC-30 50-CCTCTCCTAGACTCTCATTGGG-30
IL-, interleukin-; SMPDL3B, sphingomyelin phosphodiesterase acid-like 3; TGF, transforming growth factor; TNF, tumour necrosis factor; TSP1, thrombospondin 1.
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Fig. 1. TSP1 expression is increased in mouse NASH livers. C57BL6 male mice fed an AMLN-diet for 3 months or 8 months developed steatosis or NASH,
respectively. (A) Representative images of H&E and Masson staining, and NAFLD activity scores. (B) Liver Tsp1 mRNA levels. (C) Liver TSP1 protein levels. (D)
Representative images of immunohistochemical staining for liver TSP1. Positive staining is in brown and indicated by the arrowhead; Data are mean ± SE (n = 4–6
mice/group). *p <0.05, **p <0.01 (1-way ANOVA); (E–G) Analysis of Tsp1 expression in a single-cell RNA sequence data set from mouse NASH livers (GSE129516)
showing that Tsp1 (Thbs1) was upregulated in macrophages, cholangiocytes, and HSCs from NASH livers. AMLN, amylin liver NASH; HSCs, hepatic stellate cells;
NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; TSP1 (THBS1), thrombospondin 1.
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levels of liver steatosis, inflammation and fibrosis (Fig. S4C–F).
These data suggest that hepatocyte-derived TSP1 did not
contribute significantly to diet-induced obesity and its associated
NAFLD and NASH, which is consistent with the earlier described
liver scRNA-seq data (Figs S1 and S2).
SMPDL3B expression is increased in livers from Tsp1DMɸ mice,
accompanied by reduced liver TLR4 signalling
Liver RNA-seq analysis was performed to further determine the
mechanisms underlying the protective effect of macrophage-
specific TSP1 deficiency on HFD-induced liver phenotype
(Fig. 2). There were 367 significantly upregulated genes and 162
downregulated genes in Tsp1fl/fl mice fed a HFD vs. a LFD, respec-
tively. Kyoto Encyclopedia of Genes and Genomes (KEGG)
enriched pathways revealed several upregulated pathways, such
as the focal adhesion, TNF-a, extracellular matrix (ECM)–receptor
interaction and phagosome pathways. A comparison of HF-fed
Tsp1DMɸ with HF-fed Tsp1fl/fl mice identified 31 upregulated and
16 downregulated genes. As expected, the TNF-a and nuclear
factor (NF)-jB pathways were significantly reduced in livers from
HFD-fed Tsp1DMɸmice (Fig. 3A). Thiswas consistentwith previous
studies showing that TSP1-null macrophages had a reduced
proinflammatory phenotype.19 Sphingomyelin phosphodies-
terase acid-like 3B (Smpdl3b) was one of the differentially
regulated genes (Fig. 3B). It is a glycosylphosphatidylinositol
(GPI)-anchored membrane protein on macrophages and nega-
tively regulates TLR signalling.31 Increased Smpdl3b in the liver
fromHFD-fed Tsp1DMɸmice was confirmed by qPCR (Fig. 3C). This
alteration was associated with reduced TLR4 and proin-
flammatory cytokine (e.g. Tnf-a, Il-1b) expression (Fig. 3D,E). In
addition, Smpdl3b levels in adipose tissue were comparable
among all groups (data not shown), suggesting a tissue-specific
effect of TSP1 on the regulation of Smpdl3b levels.
SMPDL3B negatively regulates TSP1-induced macrophage
proinflammatory status
TSP1 is an important regulator of macrophage function. TSP1-
null bone marrow-derived macrophages (BMDMs) have a
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Fig. 2. Macrophage-specific TSP1 deficiency protects mice against diet-induced NAFLD/NASH.Male wild-type Tsp1fl/fl mice and Tsp1Dmɸ mice were fed either a
LFD or HFD for 8 months. (A) Body weight changes in mice. (B) Liver weight and triglyceride levels from 4 groups of mice. (C) Plasma ALT and AST levels from
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reduced proinflammatory phenotype,19 whereas TSP1 treatment
stimulates macrophages to produce proinflammatory cytokines,
associated with increased TLR4 expression and NF-jB activity.18
Despite research showing that SMPDL3B negatively regulates
TLR signalling in macrophages,31 whether SMPDL3B has a role in
TSP1-induced macrophage activation was unclear and, thus, was
investigated here.
BMDMs isolated from TSP1-null mice had increased SMPDL3B
levels, associated with reduced proinflammatory cytokine pro-
duction (Fig. S5). TSP1 treatment downregulated Smpdl3b
expression in RAW264.7 cells (Fig. 4A,B), which was associated
with increased expression of proinflammatory cytokines
(Fig. 4C), indicating that TSP1 suppresses macrophage Smpdl3b
expression. Moreover, overexpression of Smpdl3b abolished
TSP1-induced IL-1b and TNF-a expression as well as secretion in
RAW264.7 cells (Fig. 4D–E). To confirm the above findings in
primary liver macrophages, KCs from 8-week-old male C57BL6
mice were isolated and utilised in the experiment. The purity of
these cells was demonstrated by F4/80 immunofluorescence
staining (Fig. 5A). Similarly, overexpression of Smpdl3b in KCs
abolished TSP1-induced proinflammatory cytokine production
(Fig. 5B–D). Collectively, these data suggest that SMPDL3B
negatively regulates TSP1-induced macrophage activation.
Discussion
TSP1 is a multifunctional secreted matricellular protein that is
involved in the pathogenesis of various diseases, such as car-
diovascular disease, renal complications, obesity, and insulin
resistance. However, the role of TSP1 in NAFLD/NASH is largely
unknown.16,17 By using tissue-specific TSP1-knockout mice, we
demonstrated that macrophage-specific TSP1 deletion but not
adipocyte-specific TSP1 deletion protected mice against
obesity-associated liver injury, accompanied by reduced liver
inflammation and fibrosis. Importantly, this protection was
independent of the levels of obesity and hepatic steatosis.
Mechanistically, macrophage-derived TSP1 suppresses
Smpdl3b expression in liver through an autocrine effect,
amplifying liver proinflammatory signalling and promoting
NAFLD progression.
These in vivo data provide, for the first time, compelling ev-
idence for the significant contribution of macrophage-derived
TSP1 to obesity-associated NAFLD/NASH. The role of macro-
phages in the development and progression of NAFLD is sup-
ported by previously published experimental and clinical
data.4,5,8,11,32,33 In liver, KCs and infiltrating MDMs are two he-
patic macrophage populations that change dramatically during
NASH development.4,7,8,10–12 Recent studies demonstrated that
KCs and MDMs have distinct morphology and transcriptional
profiles in experimental NASH models.4,8 Moreover, infiltrating
MDMs produce more TSP1 in NASH livers than do KCs.4 Given
that KCs have a role in the initiation and/or onset of NAFLD,34,35
infiltrating MDM-derived TSP1 might stimulate NAFLD progres-
sion. Consistently, we found that macrophage-specific TSP1
deletion protected mice from steatohepatitis and fibrosis. Inter-
estingly, diet-induced steatosis was not improved in
macrophage-specific TSP1-null mice, although these mice had
reduced hepatic TLR4 or TNFa levels. Research has shown that
TNF-a stimulated sterol regulatory element binding protein-1 c
(SREBP1c) expression and induced de novo lipogenesis and he-
patic steatosis.36 However, in the current study, the expression of
genes relating to the hepatic lipid metabolism (e.g. Cd36, Srebp1,
Fas, Scd1, and Dgat1 and 2) (data not shown) was comparable in
livers between wild-type and macrophage-specific TSP1-null
mice. Therefore, other mechanisms warrant further investiga-
tion in future studies.
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Our results suggest monocyte and/or macrophage-derived
TSP1 as a therapeutic target for obesity-associated NASH. How-
ever, how monocytes and/or macrophages produce more TSP1
under obese conditions is unknown. Under obese conditions,
factors including fatty acids (FFA) and bacterial endotoxins [i.e.
lipopolysaccharides (LPS) resulting from small intestinal bacte-
rial overgrowth and increased intestinal permeability] have been
reported as putative factors for macrophage activation and NASH
development.7,10,37–39 Both FFA and LPS stimulate TSP1 expres-
sion in monocytes and/or macrophages (including human THP-1
monocytes and/or macrophages and BMDM). Interestingly,
neither T cells (T cells, T helper type [Th] 1 or Th17 cells) nor
dendritic cells (DCs) respond to LPS to produce TSP1.40–42
Collectively, these studies suggest that factors (e.g. LPS or FFA)
involved in gut–liver and adipose–liver crosstalk drive TSP1
expression in liver macrophages and contribute to NAFLD
progression.
Research previously demonstrated a novel role for TSP1 in
both the recruitment and proinflammatory activation of macro-
phages.18 In the current study, SMPDL3B was identified as a new
mediator of TSP1-induced macrophage proinflammatory activa-
tion in liver. SMPDL3B is a GPI-anchored membrane-associated
protein with homology to acid sphingomyelinase (ASMase) and
is involved in sphingomyelin catabolism.43 SMPDL3B also has a
role in podocyte injury from diabetic nephropathy or focal
segmental glomerulosclerosis44,45 as well as in inflammatory
processes. A negative regulatory role in innate immune signal-
ling has been identified in macrophages, where SMPDL3B is
found on the cell surface. Its knockdown altered cellular lipid
composition and membrane fluidity changes, leading to
enhanced responsiveness to TLR stimulation.31 However,
whether SMPDL3B is involved in NAFLD/NASH development is
unknown, although accumulating evidence suggests the contri-
bution of altered sphingolipid metabolism to NAFLD.46 In the
current study, SMPDL3B was increased in livers from
macrophage-specific TSP1-deficient mice, associated with
reduced liver TLR4 and proinflammatory cytokine expression.
Interestingly, SMPDL3B levels in adipose tissue were comparable
between wild-type and knockout mice, suggesting that
SMPDL3B specifically negatively regulates TSP1-induced liver
macrophage/KC activation. This tissue-specific effect highlights
the potential involvement of SMPDL3B in the development
and progression of NAFLD/NASH, which warrants further
investigation.
In addition to regulating liver macrophage proinflammatory
status, macrophage-derived TSP1 might directly modulate the
function of other liver cells, such as hepatocytes, stellate cells or
sinusoidal ECs, and impact the development and progression of
NAFLD/NASH through paracrine effects.17,47,48 TSP1 inhibition or
knockdown in cultured stellate cells attenuated TGF-b-induced
stellate cell activation (e.g. production of a-SMA and collagen).17
In addition, platelet-derived growth factor-induced TSP1
expression in hepatic SCs is a prerequisite for the effect of TGF-b
on SC activation.48 These studies suggest a role for TSP1 in
modulating SC function and its contribution to liver fibrosis.
TSP1 also causes a dose-dependent loss of fenestrae in liver si-
nusoidal ECs and affects their function.49 Together with our re-
sults of the effect of TSP1 on macrophage function, these
additional effects of TSP1 together contribute to obesity-
associated NAFLD/NASH development and progression.
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In summary, by using tissue-specific TSP1-knockout mice, our
research reveals a crucial role of macrophage-derived TSP1 in
obesity-associated NAFLD/NASH development and progression.
It also suggests macrophage-derived TSP1 as a therapeutic target
for obesity-associated comorbidities.
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